J. Feinberg

发表

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

S. Lee, H. Kessler, T. Schacker, 1997, The Journal of infectious diseases.

Trends in Hepatitis B Infection and Immunity among Women of Childbearing Age in the United States.

N. Terrault, J. Feinberg, Tatyana Kushner, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brucella Endocarditis in Persons Who Inject Drugs

T. Lamarre, J. Feinberg, John M Cafardi, 2020, Open forum infectious diseases.

Endocarditis as a Marker for New Epidemics of Injection Drug Use

J. Feinberg, Susan Keeshin, 2016, The American journal of the medical sciences.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

A. Collier, M. Fischl, P. Tebas, 2007, AIDS.

The opioid crisis and HIV in the USA: deadly synergies

S. Shoptaw, C. Beyrer, F. Altice, 2021, The Lancet.

Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.

K. Squires, J. Currier, J. Mrus, 2013, AIDS patient care and STDs.

Foscarnet Therapy for Ganciclovir-Resistant Cytomegalovirus Retinitis in Patients with AIDS

M. Jacobson, J. Feinberg, W. Drew, 1991 .

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

S. Spector, D. Finkelstein, S. Bozzette, 1995, The New England journal of medicine.

The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection.

C. Hamilton, A. Dobs, J. Cofrancesco, 1999, The American journal of medicine.

Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

M. Heo, L. Taylor, A. Karasz, 2019, Contemporary clinical trials.

Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus.

S. Ostroff, R. Spiegel, C. Horsburgh, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Opportunistic Fungal Infection Associated With COVID-19

T. Lamarre, J. Feinberg, John M Cafardi, 2021, Open forum infectious diseases.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

D. Katzenstein, K. Tashima, P. Sax, 2011, The Journal of infectious diseases.

Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.

C. Fichtenbaum, J. Currier, J. Feinberg, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations

Mary E. Wilson, J. Hughes, J. Phair, 1995 .

Treatment and Prophylaxis of Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy

J. Feinberg, 2001 .

A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection

H. Waskin, S. Spector, D. Finkelstein, 1995 .

Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. The AIDS Clinical Trials Group.

D. Finkelstein, D. Cotton, J. Feinberg, 1993, Journal of acquired immune deficiency syndromes.

How do patients with HIV/AIDS understand and respond to health value questions?

M. Yi, J. Mrus, J. Tsevat, 2006, Journal of General Internal Medicine.

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

J. Bartlett, R. Lewis, T. Flynn, 1991 .

Sex-Based Outcomes of Darunavir–Ritonavir Therapy

K. Squires, J. Currier, C. Zorrilla, 2010, Annals of Internal Medicine.

The case for expanding human immunodeficiency virus testing.

J. Feinberg, 2006, Mayo Clinic proceedings.

Using the electronic medical record to increase testing for HIV and hepatitis C virus in an Appalachian emergency department

S. Davis, Ian B. K. Martin, O. Lander, 2020, BMC Health Services Research.

Sex Differences in Characteristics of Patients with Infective Endocarditis: A Multicenter Study

M. Bates, A. Irfan, M. Fisher, 2022, Journal of Clinical Medicine.

Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group.

R. Chaisson, D. Finkelstein, W. Powderly, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection.

J. Metcalf, R. Davey, M. Baseler, 1990 .

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.

J. Metcalf, R. Davey, J. Kovacs, 1990, Annals of internal medicine.

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The cytomegalovirus retreatment trial

J. Phair, A. Wu, A. Friedman, 1996 .

Truvada PrEP: Why I Voted “Yes”

J. Feinberg, 2012, Annals of Internal Medicine.

Concurrent Alcohol and Opioid Use Among Harm Reduction Clients.

E. Winstanley, J. Feinberg, A. Stover, 2020, Addictive behaviors.

Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Prognosis after triple-class failure.

J. Feinberg, 2003 .

The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis

P. Friedmann, D. Seal, W. Miller, 2022, Addiction Science & Clinical Practice.

Corticosteroids as adjunctive therapy for Pneumocystis pneumonia in patients with AIDS.

P. Meier, H. Masur, J. McCutchan, 1991, The New England journal of medicine.

Mechanism of indinavir-induced hyperbilirubinemia.

R. Green, S. Zucker, K. Sherman, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s)

A. Collier, S. Evans, M. Fischl, 2007, Journal of acquired immune deficiency syndromes.

Bacterial infections in HIV disease.

J. Currier, J. Feinberg, 1995, AIDS clinical review.

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.

J. Kahn, P. Volberding, M. Fischl, 1993, Journal of acquired immune deficiency syndromes.

Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).

W. Bell, J. Chulay, J. Feinberg, 1997, Medicine.

A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic

K. Buchacz, H. Hagan, S. Strathdee, 2022, International Journal of Drug Policy.

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

M. Saag, A. Landay, J. Enejosa, 2016, AIDS.

Text Message Reminder–Recall to Increase HPV Immunization in Young HIV-1-Infected Patients

J. Feinberg, Susan Keeshin, 2017, Journal of the International Association of Providers of AIDS Care.

Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.

J. Feinberg, A. Japour, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection.

James R. Allen, J. Phair, R. Chaisson, 1993, Journal of acquired immune deficiency syndromes.

Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation.

J. Feinberg, A. Wilkin, 2000, Oncology.

The clinical of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no or

M. Jacobson, C. Benson, D. Wohl, 2013 .

Evaluation of dolutegravir safety for the treatment of HIV-1

J. Feinberg, Susan Keeshin, 2015, Expert opinion on drug safety.

Saquinavir Soft Gelatin Capsule

J. Feinberg, J. Gill, 2001, Drug safety.

HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study.

J. Feinberg, G. Fusco, S. Becker, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Health needs of HIV-infected women in the United States: insights from the women living positive survey.

K. Squires, J. Aberg, S. Storfer, 2011, AIDS patient care and STDs.

Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.

J. Feinberg, 2003, AIDS clinical care.

Opioid use disorder and rural America

J. Feinberg, W. Akhtar, 2021 .

Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?

D. Krakower, J. Feinberg, D. Daskalakis, 2020, Annals of Internal Medicine.

Changes in religiousness and spirituality attributed to HIV/AIDS

A. Leonard, M. Szaflarski, J. Tsevat, 2006, Journal of General Internal Medicine.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Spirituality and religion in patients with HIV/AIDS

A. Leonard, A. Peterman, K. Pargament, 2006, Journal of General Internal Medicine.

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

C. Yiannoutsos, C. Fichtenbaum, M. Saag, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

B. Clotet, M. Saag, A. Antinori, 2014, The Lancet.

Establishing Peer Recovery Support Services to Address the Central Appalachian Opioid Epidemic

S. Davis, E. Winstanley, H. Linn, 2021, Journal of Appalachian health.

Fever in patients with HIV infection.

J. Bartlett, J. Feinberg, M. Sullivan, 1996, Infectious disease clinics of North America.

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

M. Polis, S. Spector, D. Dieterich, 1998, Archives of internal medicine.

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.

H. Waskin, D. Finkelstein, R. Steigbigel, 1992, The New England journal of medicine.

Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naive Adults

Jane Yeo, Judith Feinberg, M. Fischl, 1999, Antiviral therapy.

Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection

C. Fichtenbaum, C. Benson, J. Griffiths, 2000, AIDS.

Update on management of opportunistic infections in patients with HIV infection

J. Bartlett, J. Feinberg, 1993 .

Pneumocystis carinii pneumonia: a clinical review.

J. Feinberg, A. Wilkin, Aimee Wilkin, 1999, American family physician.

Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group.

D. Kuritzkes, C. Farthing, R. Steigbigel, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

H. Waskin, D. Finkelstein, S. Koletar, 1995, The New England journal of medicine.

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.

Paul E. Méndez, R. Haubrich, R. Brookmeyer, 1997, American journal of ophthalmology.

Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.

J. McCune, K. Komanduri, J. Lalezari, 2001, The Journal of infectious diseases.

Comparison of Three Regimens for Treatment of Mild to Moderate Pneumocystis carinii Pneumonia in Patients with AIDS: A Double-Blind, Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine

Albert Wu, Judith Feinberg, Tony Cheung, 1996, Annals of Internal Medicine.

Guidelines for preventing opportunistic infections among HIV-infected persons - 2002

Keiji Fukuda, Mark A. Jacobson, Cynthia L. Sears, 2002 .

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. Jacobson, S. Weller, J. Gallant, 1994, Antimicrobial Agents and Chemotherapy.

Current and Future Treatment Guidelines for HIV

J. Feinberg, 2012 .

Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030

C. Crumpacker, S. Spector, D. Jabs, 2009, HIV clinical trials.

A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection

D. Cooper, M. Youle, P. Griffiths, 1998 .

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

M. Youle, P. Griffiths, M. Gill, 1998, The Journal of infectious diseases.

Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

Ann Collier, Judith Feinberg, A. Collier, 1995, Annals of Internal Medicine.

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.

M. Wulfsohn, R. Gelber, W. Borkowsky, 1991, The New England journal of medicine.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Low-dose zalcitabine-related toxic neuropathy

G. D. Dal Pan, J. McArthur, D. Cornblath, 1996, Neurology.

Phase II dose‐ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)

Roger B. Davis, M. Wulfsohn, C. Crumpacker, 1994 .

Cytomegalovirus retinitis and low CD4+ T-lymphocyte counts.

D. Jabs, J. Dunn, J. Feinberg, 1995, The New England journal of medicine.

Patterns of opportunistic infections in patients with HIV infection.

G Molenberghs, G. Molenberghs, J. Kahn, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection

J. Feinberg, J. Robertson, 2012, Expert opinion on pharmacotherapy.

ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA

M. Baseler, A. Fauci, J. Kovacs, 1988, The Lancet.

Prevalence and Genotypic Variability of TTV in HIV-Infected Patients

K. Sherman, J. Feinberg, S. Rouster, 2001, Digestive Diseases and Sciences.

The case of Scott County: injection drug use and the HIV and hepatitis C virus outbreak

J. Feinberg, John M Cafardi, 2021 .

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine

M. Lederman, D. Kuritzkes, J. Mellors, 2013, PloS one.

Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.

Paul E. Méndez, R. Haubrich, J. Phair, 1995, Archives of internal medicine.

Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.

M. Jacobson, J. Feinberg, W. Drew, 1991, The Journal of infectious diseases.

Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.

Paul Griffiths, Victor De Gruttola, Vincent C Emery, 2002, The Journal of infectious diseases.

Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group

C. Sabin, P. Griffiths, V. Emery, 1999, The Journal of infectious diseases.

Long-Term Efficacy and Safety of Twice-Daily Saquinavir Soft Gelatin Capsules (SGC), with or without Nelfinavir, and Three Times Daily Saquinavir-SGC, in Triple Combination Therapy for HIV Infection: 100-Week Follow-Up

J. Feinberg, J. Goodrich, R. Greenberg, 2003, Antiviral therapy.

Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173.

D. Pattison, C. Hendrix, R. Hafner, 1999, Journal of acquired immune deficiency syndromes.

Management of Newly Diagnosed HIV Infection

J. Feinberg, Susan Keeshin, 2011, Annals of Internal Medicine.

The status of CMV viral load testing.

J. Feinberg, 1996, AIDS clinical care.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

S. Hammer, M. Saag, A. Collier, 2003, The Journal of infectious diseases.

Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization

M. Bates, A. Irfan, M. Fisher, 2022, PloS one.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

M. Lederman, D. Kuritzkes, C. Flexner, 2013, The Journal of infectious diseases.

Change in quality of life after being diagnosed with HIV: a multicenter longitudinal study.

A. Leonard, M. Szaflarski, J. Mrus, 2009, AIDS patient care and STDs.

Spirituality and Religion in Patients with HIV/AIDS

A. Leonard, K. Pargament, A. Justice, 2009, Journal of General Internal Medicine.

Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?

F. Altice, J. Feinberg, Katherine M Rich, 2018, Current HIV/AIDS Reports.

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

J. Montaner, M. King, S. Brun, 2004, The Journal of infectious diseases.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients

A. Perelson, B. Aronow, J. Blackard, 2014, Science Translational Medicine.

Withdrawal of prophylaxis against Pneumocystis carinii pneumonia

J. Feinberg, 1999, The Lancet.

Sex-Based Outcomes of Darunavir–Ritonavir Therapy: The GRACE (Gender, Race, and Clinical Experience) Study

K. Squires, J. Currier, C. Zorrilla, 2010 .

Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma.

J. Metcalf, M. Baseler, J. Kovacs, 1988, Lancet.

Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

T. Navin, J. Feinberg, W. Hughes, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Cytomegalovirus Peripheral Retinitis in Patients with AIDS

W. Freeman, S. Spector, D. Dieterich, 1993 .

Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).

J. Bartlett, R. Lewis, T. Flynn, 1992, Controlled clinical trials.

The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

C. Sabin, P. Griffiths, V. Emery, 1998, The Journal of infectious diseases.

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

S. Hammer, J. Falloon, H. Masur, 2002, AIDS.

Tackle the epidemic, not the opioids

J. Feinberg, 2019, Nature.

Incidence Rate of and Factors Associated with Loss to Follow-up in a Longitudinal Cohort of Antiretroviral-Treated HIV-Infected Persons: An AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Analysis

R. Bosch, A. Collier, S. Koletar, 2011, HIV clinical trials.

Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey

S. Magnusson, R. Westergaard, X. Levander, 2022, Journal of General Internal Medicine.

Barriers to Implementation of Opioid Overdose Prevention Programs in Ohio

C. Wilder, E. Winstanley, Angela Clark, 2016, Substance abuse.

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

P. Sax, A. Hsu, D. Kempf, 2002, The Journal of infectious diseases.

Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients

A. Ganesan, R. Kaplan, J. Stein, 2008, Circulation.

M. Saag, K. Squires, J. Currier, 2011, AIDS research and treatment.

Tipranavir: a new option for the treatment of drug-resistant HIV infection.

Z. Temesgen, J. Feinberg, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia.

T. Hulsey, C. Lilly, J. Feinberg, 2020, American Journal of Preventive Medicine.

Using Health Information Technology to Create Pathways for Hepatitis C Treatment and Cure in West Virginia.

A. Baus, C. Pollard, J. Feinberg, 2022, Perspectives in health information management.

Effect of co‐administration of efavirenz and nelfinavir on the pharmacokinetics of indinavir

A. Collier, J. Feinberg, R. Dicenzo, 2005 .

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

Heather Ribaudo, Judith Feinberg, M. Chesney, 2005, The Journal of infectious diseases.

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

R. Hyzy, D. Talmor, C. Cairns, 2017, The Lancet Respiratory Medicine.

Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis

M. Jacobson, B. Polsky, M. Heinemann, 1994, Antimicrobial Agents and Chemotherapy.

A qualitative assessment of discharge against medical advice among patients hospitalized for injection-related bacterial infections in West Virginia.

R. Pollini, M. Haut, J. Feinberg, 2021, The International journal on drug policy.

Prevention and Initial Management of HIV Infection

J. Feinberg, Susan Keeshin, 2022, Annals of Internal Medicine.

Intravitreal ganciclovir salvage therapy for cytomegalovirus retinitis in AIDS: AIDS clinical trials group protocol 085

Roger B. Davis, B. Polsky, M. Heinemann, 1996 .

Mechanism of indinavir-induced hyperbilirubinemia

R. Green, S. Zucker, K. Sherman, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.

L. Lander, E. Winstanley, C. Xie, 2021, Journal of affective disorders.

Consumer discernment of fentanyl in illicit opioids confirmed by fentanyl test strips: Lessons from a syringe services program in North Carolina.

Sarah E. Duhart Clarke, J. Zibbell, J. Feinberg, 2021, The International journal on drug policy.

It's in your blood.

J. Feinberg, 2011, Positively aware : the monthly journal of the Test Positive Aware Network.

A. Wu, D. Jacobson, J. Feinberg, 2003, Journal of clinical epidemiology.

Update on opportunistic infections.

P. Reiss, C. Leport, J. Feinberg, 1997, Project Inform perspective.

The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit

M. Jacobson, C. Benson, D. Wohl, 2013, PloS one.

Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

Z. Temesgen, J. Feinberg, 2006, Current opinion in investigational drugs.

A Randomized Study of Immune Plasma for the Treatment of Severe Influenza

M. Hughes, C. Cairns, J. Metcalf, 2017 .

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

M. Jacobson, M. Chown, B. Kuppermann, 1993, The Journal of infectious diseases.

Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

David R. Holtgrave, M. Alter, J. Phair, 2002, Annals of internal medicine.

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

J. Falloon, H. Masur, S. Bozzette, 1993, The New England journal of medicine.

New developments in the treatment of Pneumocystis carinii pneumonia.

J. Feinberg, J. Feinberg, F. Sattler, 1992, Chest.

Reviews Of Anti‐infective Agents: Tipranavir: A New Option for the Treatment of Drug‐Resistant HIV Infection

Z. Temesgen, J. Feinberg, 2007 .

Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial

A. Wu, K. Freedberg, D. Revicki, 2002, Quality of Life Research.

Current status of HIV therapy: II. Opportunistic diseases.

J. Feinberg, D. Hoth, 1991, Hospital practice.

Endocarditis as a Marker for New Epidemics of Injection Drug Use

J. Feinberg, Susan Keeshin, 2016, The American journal of the medical sciences.

Supportive environments during the substance use disorder epidemic in the rural United States: Provider support for interventions and expectations of interactions with providers.

J. Feinberg, Dolores Albarracín, R. Gross, 2022, Social science & medicine.

Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

David R. Holtgrave, M. Alter, J. Phair, 2002, Annals of internal medicine.